Optimal treatment timing significantly impacts survival in localized colon, lung, and pancreatic cancers.

• 68.7% of colon cancer, 70.6% of non-small cell lung cancer (NSCLC), and 22.6% of pancreatic cancer patients received optimal care.
• Patients receiving optimal care had much lower death risk: colon cancer HR 0.45, NSCLC HR 0.35, pancreatic cancer HR 0.46.

Optimal care’s survival benefit diminishes for patients from vulnerable neighborhoods, highlighting the need for tailored interventions.

• Addressing social vulnerabilities may improve outcomes in high-risk populations.